No Data
No Data
No Data
Betta Pharmaceuticals (SZSE:300558) Sheds CN¥988m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
If you love investing in stocks you're bound to buy some losers. But long term Betta Pharmaceuticals Co., Ltd. (SZSE:300558) shareholders have had a particularly rough ride in the last three year. S
Private Companies Among Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 5.1% Last Week
Key Insights Significant control over Betta Pharmaceuticals by private companies implies that the general public has more power to influence management and governance-related decisions 50% of the bu
Some Shareholders Feeling Restless Over Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Ratio
With a price-to-earnings (or "P/E") ratio of 45.3x Betta Pharmaceuticals Co., Ltd. (SZSE:300558) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E
Does The Market Have A Low Tolerance For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Mixed Fundamentals?
Betta Pharmaceuticals (SZSE:300558) has had a rough three months with its share price down 12%. It seems that the market might have completely ignored the positive aspects of the company's fundament
Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% Loss
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of Betta Pharmaceuticals Co., Ltd. (SZSE:300558) have had an unfortunate run in the
Betta Pharmaceuticals Co., Ltd. (SZSE:300558) Not Flying Under The Radar
Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) price-to-earnings (or "P/E") ratio of 59.6x might make it look like a strong sell right now compared to the market in China, where around half of the co
No Data